New funding: OncoResponse raised a $40.6M Series C investment round as it continues to develop antibodies that fight cancer. The science: The company examined the immune systems of cancer patients who responded unusually well to immunotherapy treatments. It aims to harness antibodies from those immune systems to make new immunotherapy treatments for patients whose systems do not respond well to existing options. Leadership: The company is led by CEO and founder Clifford Stocks, who previously led Theraclone Sciences and was a longtime exec at ICOS Corporation, which was acquired by Lilly for $2.3 billion in 2007.